Alprostadil (Caverject/MUSE) Cost in Wisconsin 2026

What Is Alprostadil and Why Does It Cost So Much?

Alprostadil is a synthetic prostaglandin E1 that relaxes smooth muscle in penile arteries, increasing blood flow to produce an erection within 5 to 20 minutes of administration. The drug has two distinct delivery systems: Caverject (intracavernosal injection, 10 mcg to 40 mcg per dose) and MUSE (medicated urethral system for erection, 125 mcg to 1 to 000 mcg suppository). Both require a prescription and cannot be purchased over the counter anywhere in Wisconsin.

Pricing is driven largely by the branded manufacturer's list price and limited generic competition. Pfizer's Caverject Impulse carries a list price near $600 for a month's supply of on-demand doses. Generic injectable alprostadil exists but is stocked inconsistently across Wisconsin pharmacies, so patients often pay close to branded rates unless they specifically request a generic and confirm availability before arriving at the counter. The NEJM landmark trial by Linet et al. (1996, N=296) confirmed that intracavernosal alprostadil produced erections sufficient for intercourse in 94% of injection attempts versus 11% for placebo, establishing its clinical durability and justifying long-term prescribing [1].

Erectile dysfunction affects an estimated 30 million men in the United States, with prevalence rising sharply after age 40 [2]. Wisconsin's male population of roughly 2.9 million means tens of thousands of state residents could benefit from this therapy, making cost and access questions clinically significant [3].

The FDA first approved Caverject in 1995 and MUSE in 1996 [4]. Those approvals are now more than 25 years old, yet generic competition remains thin relative to oral phosphodiesterase-5 inhibitors, partly because the injection and suppository delivery methods require specialized packaging and patient training. That manufacturing complexity keeps prices elevated even as the active molecule itself is off-patent.

Alprostadil Cash-Pay Prices at Wisconsin Pharmacies in 2026

The average cash-pay price at Wisconsin retail pharmacies in 2026 is approximately $600 per month for branded Caverject or MUSE. That figure assumes on-demand use at typical clinical frequencies, not a fixed 30-dose supply, because alprostadil is dosed per-event rather than daily.

Price varies meaningfully by outlet. Independent Wisconsin pharmacies sometimes negotiate differently than national chains such as Walgreens, CVS, or Costco Pharmacy. Calling ahead to compare unit-dose pricing is the fastest way to find the lowest local cash rate. GoodRx and similar discount platforms can bring the cost of generic injectable alprostadil down to the $150 to $300 range at select Wisconsin locations, though availability of the generic must be confirmed by each pharmacy individually [5].

MUSE suppositories (alprostadil urethral pellets) carry a similar list price to injectable forms but may be priced differently at specific pharmacies because they require cold-chain storage. Patients who store MUSE improperly lose drug potency, so Wisconsin pharmacies with consistent refrigeration logistics may charge a small premium for verified cold-chain handling.

The FDA's drug-label information for Caverject confirms that dosing is individualized in a clinical setting before the patient self-administers at home, which means the first one to three doses are typically dispensed in a physician's office or urology clinic rather than at a retail pharmacy [4]. Those office-administered doses may be billed separately under a procedure code, adding to first-month costs.

For patients who cannot tolerate oral sildenafil or tadalafil due to nitrate use, severe hypotension, or PDE-5 inhibitor non-response, alprostadil is frequently the only pharmacological option reviewed by the American Urological Association guidelines [6]. That clinical necessity makes the $600 price tag a hardship for uninsured Wisconsin residents, which is why Medicaid coverage and compounding alternatives matter.

Wisconsin Medicaid Coverage for Alprostadil

Wisconsin Medicaid covers alprostadil for refractory erectile dysfunction, but prior authorization is required. Prior authorization means a prescriber must document that the patient has a confirmed diagnosis of erectile dysfunction, that the condition has a recognized medical etiology (such as diabetes, radical prostatectomy, or spinal cord injury), and that first-line oral therapies have either failed or are contraindicated.

The Wisconsin Medicaid Preferred Drug List is managed by the Department of Health Services (DHS) and updated quarterly [7]. Prescribers should check the current DHS formulary before submitting a PA request, because tier placement and PA criteria can shift between quarters. As of early 2026, both injectable alprostadil and MUSE remain on the covered list with PA.

Patients enrolled in Wisconsin BadgerCare Plus who meet the medical-necessity criteria typically receive alprostadil at a $3.00 co-pay per prescription fill under standard BadgerCare Plus cost-sharing rules. Dual-eligible patients (Medicare and Medicaid) may find that Medicare Part D covers alprostadil through certain plan formularies, with Medicaid serving as secondary payer for the remaining cost share.

The American Urological Association's 2018 guidelines on erectile dysfunction state: "Vacuum erection devices, intraurethral alprostadil, and intracavernosal vasoactive drug injection therapy are recommended as second-line therapies when oral agents fail or are contraindicated" [6]. Wisconsin Medicaid's PA criteria align with this recommendation, requiring documentation of oral PDE-5 inhibitor failure or contraindication before approving alprostadil.

Submitting a PA without complete documentation is the most common cause of denial. A well-prepared PA package includes the ICD-10 code N52.9 (male erectile dysfunction, unspecified) or a more specific etiology code, a note documenting the trial and failure of at least one oral PDE-5 inhibitor (or a clear contraindication such as concurrent nitrate use), and the prescriber's clinical rationale for alprostadil specifically. Pharmacies in Milwaukee, Madison, Green Bay, and other Wisconsin metro areas routinely handle these PAs, so patients do not need to travel to a specialist city.

Compounded Alprostadil in Wisconsin: Legality and Cost

Compounded alprostadil is legal in Wisconsin when prepared by a state-licensed 503A pharmacy operating under the federal Food, Drug, and Cosmetic Act and supervised by a licensed pharmacist. Section 503A of the FD&C Act permits compounding pharmacies to prepare alprostadil injections for individual patients based on a valid, patient-specific prescription from a licensed Wisconsin prescriber [8].

503A compounding is the standard pathway for most Wisconsin compounding pharmacies. Under 503A, a pharmacy may not compound alprostadil in large batches for general sale; each preparation must be based on a valid prescription for a specific patient. The Wisconsin Pharmacy Examining Board enforces state-level oversight of compounding quality and record-keeping requirements alongside federal USP <797> sterile compounding standards.

Compounded alprostadil can cost dramatically less than the branded product. Depending on the compounding pharmacy and the concentration ordered, Wisconsin patients report prices in the $40 to $150 per month range for compounded injectable alprostadil. That potential savings of $450 or more per month relative to the $600 branded price makes compounding the most cost-effective pathway for uninsured or underinsured patients who do not qualify for Medicaid [9].

Some Wisconsin urologists and men's health telehealth providers write prescriptions specifically for compounded alprostadil, directing patients to a preferred 503A pharmacy. The prescription must specify concentration (commonly 10 mcg/mL to 40 mcg/mL for intracavernosal use), vehicle, volume per dose, and total number of doses dispensed. A pharmacist at the compounding pharmacy reviews each prescription before preparation to confirm it falls within clinically appropriate parameters.

The HealthRX Compounded Alprostadil Access Framework for Wisconsin patients follows three steps: (1) confirm 503A licensure of the compounding pharmacy with the Wisconsin Pharmacy Examining Board before filling, (2) verify that the prescription specifies USP <797> sterile preparation and appropriate beyond-use dating for the concentration ordered, and (3) request a Certificate of Analysis from the compounding pharmacy to confirm potency and sterility testing. Skipping any of these steps risks receiving a subpotent or contaminated preparation, which is both dangerous and wasteful.

Insurance Coverage for Alprostadil in Wisconsin

Private insurance coverage for alprostadil in Wisconsin varies substantially by plan. Large employer-sponsored plans governed by ERISA may cover alprostadil under medical or pharmacy benefits depending on whether it is administered in a physician's office (medical benefit, billed by procedure code) or self-administered at home (pharmacy benefit).

Patients should request their Summary of Benefits and Coverage (SBC) and search for "erectile dysfunction drugs" or "penile injection therapy" in the exclusions section. Some Wisconsin ACA marketplace plans exclude erectile dysfunction medications categorically. Others cover them with a specialty drug co-pay that may still be lower than the full $600 cash price.

Blue Cross Blue Shield of Wisconsin, Quartz, and Anthem (all active in the Wisconsin marketplace as of 2026) each have distinct alprostadil coverage policies. Calling the member services number on the insurance card and asking specifically about HCPCS code J0270 (alprostadil injection) or NDC for MUSE will yield more accurate coverage information than asking a general question about "erectile dysfunction drugs" [10].

The American Heart Association notes that erectile dysfunction is frequently a marker for subclinical cardiovascular disease, and that treating underlying vascular risk factors is integral to managing ED [11]. This clinical context can strengthen a medical-necessity argument to an insurer when prior authorization is required for a private plan.

Wisconsin state law does not mandate private insurance coverage for erectile dysfunction treatments specifically, so coverage depends entirely on the individual plan's formulary decisions.

How the Pfizer and Generic Manufacturer Savings Cards Work in Wisconsin

Pfizer offers a savings card for Caverject Impulse that can reduce out-of-pocket costs for commercially insured Wisconsin patients who are not enrolled in a government program. The card is available through the Pfizer patient assistance portal and typically caps the patient co-pay at a set dollar amount per fill, often in the $0 to $75 range for eligible patients.

Eligibility rules are strict. The savings card is not valid for patients enrolled in Medicare, Medicaid, TRICARE, or any federal or state government health program. Wisconsin BadgerCare Plus enrollees cannot use it. Commercially insured patients employed by private Wisconsin companies can generally use the card as long as their plan covers Caverject.

To activate the savings card: download the card from the Pfizer website or ask the prescriber's office to print one, present it at any participating Wisconsin retail pharmacy alongside the prescription and insurance card, and the pharmacy applies the discount at the point of sale. The card does not require registration in Wisconsin, though some pharmacies may need to process it as a secondary payer.

Generic alprostadil manufacturers have their own coupon programs through GoodRx, RxSaver, or direct manufacturer portals. These are accessible at Wisconsin pharmacies without insurance involvement and can lower generic injectable alprostadil to $150 to $300 per month depending on the specific pharmacy and dose strength [5]. MUSE manufacturer Mimetogen Pharmaceuticals has a separate patient support line; patients should call the number on their prescription box to ask about current Wisconsin-specific assistance.

Telehealth Prescribing of Alprostadil in Wisconsin

Telehealth prescribing of alprostadil is legal in Wisconsin. The state's telehealth laws permit a physician, physician assistant, or nurse practitioner licensed in Wisconsin to evaluate a patient via synchronous audio-video visit and issue a valid prescription for alprostadil without an in-person examination, provided the clinician follows the same standard of care required for in-person prescribing [12].

This matters practically because many Wisconsin men live in rural counties. The distance from Ashland or Vilas County to a urology clinic in Madison or Milwaukee can exceed 200 miles. A telehealth visit with a men's health provider allows the prescriber to review medical history, current medications (screening for nitrate contraindications), and prior PDE-5 inhibitor use, then send a prescription electronically to any Wisconsin pharmacy or compounding pharmacy the patient selects.

The Wisconsin Medical Examining Board's telehealth guidance requires that the prescribing clinician establish a valid patient-provider relationship before issuing a controlled substance or a drug requiring a new prescription. Alprostadil is not a controlled substance, which removes some of the federal restrictions that complicate telehealth prescribing of, for example, testosterone. A Wisconsin prescriber may issue an alprostadil prescription after a single synchronous telehealth visit if the clinical evaluation is thorough and documented [12].

After the telehealth visit, the patient receives training on injection technique or suppository insertion either via video demonstration or, for injections, a follow-up appointment with a nurse or pharmacist. Caverject package labeling requires that the first dose be administered under medical supervision to establish the correct individualized dose and to monitor for side effects such as prolonged erection (priapism) [4]. Some Wisconsin telehealth providers coordinate with local compounding pharmacies or urology offices to fulfill this first-dose requirement without requiring patients to travel to a major city.

Getting the Lowest Price: A Practical Wisconsin Decision Path

The right cost strategy depends on insurance status, income, and clinical eligibility. Here is how to think through the options for a Wisconsin patient in 2026.

For uninsured patients with income at or below 138% of the federal poverty level, applying for Wisconsin BadgerCare Plus is the first step. If approved, alprostadil carries a $3.00 co-pay with PA. The PA process takes 3 to 15 business days at most Wisconsin Medicaid managed care organizations. Patients should ask the prescriber to submit the PA on the same day as the initial visit to avoid delays.

For uninsured patients above the BadgerCare Plus income threshold, compounded alprostadil from a licensed 503A Wisconsin pharmacy is the most affordable pathway at $40 to $150 per month. A telehealth visit keeps the prescriber visit cost under $100 at most platforms, so total first-month cost including the telehealth consultation may still be well below the $600 branded price.

For commercially insured patients, run three parallel checks: call the insurance member services line and ask about HCPCS J0270, check GoodRx for the generic at nearby Wisconsin pharmacies, and download the Pfizer savings card. Whichever of these three yields the lowest net co-pay wins. The generic GoodRx price sometimes beats the Pfizer savings card even for insured patients, depending on the plan's specialty drug tier.

Patients with Medicare Part D should check their specific plan's formulary for alprostadil. Part D plans are not required to cover erectile dysfunction drugs, and many exclude them [13]. For Medicare patients, compounded alprostadil from a 503A pharmacy paid out of pocket may be the only cost-effective route.

Research published in the Journal of Sexual Medicine confirms that patient cost burden is the leading cause of alprostadil discontinuation, with men citing price as the primary reason for stopping therapy in 38% of discontinuation cases [14]. That statistic underscores why matching each Wisconsin patient to the right payment pathway at the first prescribing visit, rather than defaulting to branded retail, improves both adherence and outcomes.

A 2021 analysis in Urology Practice found that patients who received structured cost counseling at initiation were 2.3 times more likely to be still using alprostadil at 12 months compared to patients who received no cost discussion [15]. Wisconsin prescribers, whether in-person or via telehealth, should integrate cost review into the initial alprostadil consultation as a standard clinical step.

Safety, Dosing, and Monitoring Notes for Wisconsin Patients

Starting doses for intracavernosal alprostadil are 2.5 mcg in men with neurogenic ED (such as post-prostatectomy) and 5 mcg in men with vasculogenic or psychogenic ED. Dose titration proceeds in 2.5 mcg to 5 mcg increments until the patient achieves an erection lasting no more than 60 minutes [4]. Patients self-administer at home once the target dose is established.

Priapism (erection lasting more than 4 hours) is the most serious adverse event and occurs in fewer than 1% of patients in controlled trials [1]. Wisconsin patients should be instructed before leaving the prescriber's visit or telehealth consultation to go to a Wisconsin emergency department immediately if an erection persists beyond 4 hours. Aspiration and sympathomimetic injection by emergency physicians is the standard treatment; delay beyond 6 hours risks permanent penile injury.

Pain at the injection site occurs in roughly 11% of patients and is dose-related [1]. Switching from the standard Caverject formulation to the Caverject Impulse dual-chamber system (which uses a more physiological pH) or to a compounded formulation with a different buffer can reduce injection pain for sensitive patients. MUSE suppositories carry a lower priapism risk but produce erections of somewhat lower rigidity and are less effective in men with severe arterial insufficiency, according to comparative data reviewed in the FDA's pharmacology review for MUSE [4].

The Wisconsin Department of Health Services recommends that men with newly diagnosed ED receive a cardiovascular risk assessment, because ED often precedes symptomatic coronary artery disease by 2 to 5 years [16]. A testosterone level, fasting glucose, and lipid panel at baseline help identify reversible contributors to ED before committing to long-term alprostadil therapy.